Recently, news broke that Toolgen is undertaking a rights offering to navigate the patent war surrounding its gene-editing technology, CRISPR. However, concerns are rising that the accompanying stock price decline might hinder their ability to secure the initially planned funding. This highlights how crucial financial capacity to cover litigation costs has become for Toolgen as it pursues patent monetization.

The Necessity and Background of the Rights Offering

According to the pharmaceutical and biotech industry on the 10th, Toolgen's CEO, Yoo Jong-sang, explained the rationale behind the rights offering at a briefing session in Yeouido, Seoul. He stated, "It's to secure the capital base needed to emerge victorious in global litigation." He further added, "The funds raised will be utilized as ammunition to solidify our win in global lawsuits and drive monetization." This underscores the significance of the lawsuits for Toolgen, given its reliance on the CRISPR-Cas9 gene-editing platform and CRISPR RNP technology.

The Landscape of the Patent War

Toolgen's patent war is unfolding on two main fronts. The first is the interference proceeding concerning the original Cas9 patent, currently underway at the U.S. Patent Trial and Appeal Board (PTAB). This process involves a competition between Toolgen, the Broad Institute, and CVC to determine who first invented the core application of CRISPR-Cas9 gene editing in eukaryotic cells. The second is the RNP patent infringement lawsuit, which Toolgen is leveraging to sue various companies in Europe and the United States.

Stock Price Decline and Funding Challenges

However, Toolgen's current stock price is significantly below the initially proposed offering price, making it highly probable that the actual funds raised will be less than originally planned. For instance, the planned issuance of 777,000 shares at an intended price of 92,000 KRW per share aimed to raise approximately 70 billion KRW. But, based on the recent closing price of 43,350 KRW, the final offering price is projected to be around 32,700 KRW per share, potentially reducing the total funds raised to about 25.4 billion KRW.

Future Outlook and Shareholder Concerns

Among shareholders, concerns about the possibility of further fundraising are also growing. One shareholder voiced at the briefing, "The currently raised funds might not be enough to see us through until 2028, potentially necessitating another rights offering next year." In response, CEO Yoo stated, "We are exploring various channels for securing funds," hinting at the possibility of additional funding through strategic investments and other avenues.

Ultimately, Toolgen's future performance hinges on its financial resilience to cover litigation expenses. Successfully defending its status as the first inventor in the Cas9 interference proceeding or securing a favorable position in the RNP patent infringement lawsuit could lead to licensing agreements, settlement fees, and royalty income. However, before such outcomes materialize, the company must first bear the litigation costs, placing Toolgen's financial stability under scrutiny.